Gian Franco Zannoni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4537427/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Local-Regional Staging of Endometrial Carcinoma: Role of MR Imaging in Surgical Planning. Radiology, 2004, 231, 372-378.	3.6	331
2	Class III β-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients. Clinical Cancer Research, 2006, 12, 2774-2779.	3.2	213
3	Possible involvement ofhMLH1, p16INK4a andPTEN in the malignant transformation of endometriosis. International Journal of Cancer, 2002, 102, 398-406.	2.3	128
4	Cyclooxygenase-2 expression in endometrial carcinoma. Cancer, 2002, 95, 801-807.	2.0	118
5	Early-stage cervical cancer: Tumor delineation by magnetic resonance imaging and ultrasound — A European multicenter trial. Gynecologic Oncology, 2013, 128, 449-453.	0.6	115
6	Uterine PEComas. American Journal of Surgical Pathology, 2018, 42, 1370-1383.	2.1	114
7	<i>>BRAF</i> (V600E) mutation analysis on liquidâ€based cytologyâ€processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathology, 2013, 121, 291-297.	1.4	104
8	Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncology, The, 2016, 17, 1137-1146.	5.1	97
9	Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and Galectin-3 expression on liquid-based fine-needle cytology. European Journal of Endocrinology, 2011, 165, 447-453.	1.9	95
10	New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines. Cancers, 2021, 13, 2623.	1.7	84
11	Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma. Biochemical Pharmacology, 2009, 78, 1374-1381.	2.0	82
12	CD133 antigen expression in ovarian cancer. BMC Cancer, 2009, 9, 221.	1.1	77
13	Histopathologic Prognostic Factors in Stage I Leiomyosarcoma of the Uterus. American Journal of Surgical Pathology, 2011, 35, 522-529.	2.1	75
14	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecologic Oncology, 2019, 154, 441-448.	0.6	74
15	p16ink4a and HPV L1 Immunohistochemistry is Helpful for Estimating the Behavior of Low-grade Dysplastic Lesions of the Cervix Uteri. American Journal of Surgical Pathology, 2008, 32, 1715-1720.	2.1	73
16	Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer. Gynecologic Oncology, 2011, 122, 573-579.	0.6	70
17	Polarisation of Tumor-Associated Macrophages toward M2 Phenotype Correlates with Poor Response to Chemoradiation and Reduced Survival in Patients with Locally Advanced Cervical Cancer. PLoS ONE, 2015, 10, e0136654.	1.1	70
18	Myometrial Invasion and Lymph Node Metastasis in Endometrioid Carcinomas: Tumor-associated Macrophages, Microvessel Density, and HIF1A Have a Crucial Role. American Journal of Surgical Pathology, 2010, 34, 1708-1714.	2.1	67

#	Article	IF	CITATIONS
19	Sox9 and Hif-2α regulate TUBB3 gene expression and affect ovarian cancer aggressiveness. Gene, 2014, 542, 173-181.	1.0	65
20	Class III βâ€ŧubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. Journal of Cellular Physiology, 2012, 227, 1034-1041.	2.0	64
21	Clinical Performance of Human Papillomavirus E6 and E7 mRNA Testing for High-Grade Lesions of the Cervix. Journal of Clinical Microbiology, 2009, 47, 3895-3901.	1.8	63
22	HuR Regulates Î ² -Tubulin Isotype Expression in Ovarian Cancer. Cancer Research, 2010, 70, 5891-5900.	0.4	60
23	Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology, 2014, 211, 632.e1.632.e8.	0.7	60
24	Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer. Oncotarget, 2015, 6, 18966-18979.	0.8	57
25	TCGA Molecular Subgroups in Endometrial Undifferentiated/Dedifferentiated Carcinoma. Pathology and Oncology Research, 2020, 26, 1411-1416.	0.9	56
26	Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer. Gynecologic Oncology, 2014, 132, 351-359.	0.6	55
27	TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma. Pathology and Oncology Research, 2020, 26, 2067-2073.	0.9	55
28	Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical–pathological and immunohistochemical study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 27-34.	1.4	54
29	Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecologic Oncology, 2005, 98, 383-389.	0.6	53
30	Endometriosis-associated clear cell carcinoma arising in caesarean section scar: a case report and review of the literature. World Journal of Surgical Oncology, 2016, 14, 300.	0.8	53
31	Chemoprevention of DMBA-induced mammary cancer in rats by dietary soy. Breast Cancer Research and Treatment, 2001, 69, 153-164.	1.1	52
32	Hyaluronic acid–paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer Chemotherapy and Pharmacology, 2011, 68, 107-116.	1.1	52
33	Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. Journal of Experimental and Clinical Cancer Research, 2012, 31, 71.	3.5	51
34	Frequent Loss of pRb2/p130 in Human Ovarian Carcinoma. Clinical Cancer Research, 2004, 10, 3098-3103.	3.2	50
35	Peritoneal Mesothelioma in Recurrent Familial Peritonitis. Journal of Clinical Gastroenterology, 1997, 24, 276-279.	1.1	48
36	Diagnostic Efficacy of Conventional as Compared to Liquid-Based Cytology in Thyroid Lesions. Acta Cytologica, 2009, 53, 659-666.	0.7	47

#	Article	IF	CITATIONS
37	Clear cell endometrial carcinoma and the TCGA classification. Histopathology, 2020, 76, 336-338.	1.6	47
38	Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial carcinoma with microsatellite instability. Cancer, 2000, 88, 2290-2297.	2.0	46
39	Uterine smooth muscle tumors of unknown malignant potential: A challenging question. Gynecologic Oncology, 2019, 154, 631-637.	0.6	46
40	Pseudo-Meigs' syndrome associated with malignant struma ovarii: a case report. Gynecologic Oncology, 2004, 94, 226-228.	0.6	44
41	Gender Influences the Class III and V β-Tubulin Ability to Predict Poor Outcome in Colorectal Cancer. Clinical Cancer Research, 2012, 18, 2964-2975.	3.2	44
42	The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer. Human Pathology, 2013, 44, 1047-1054.	1.1	44
43	Near-Infrared Imaging with Indocyanine Green for Detection of Endometriosis Lesions (Gre-Endo) Tj ETQq1 1 0.78	4314 rgB1 0.3	「Qverlock」
44	Expression of the Glioma-Associated Oncogene Homolog 1 (Gli1) in Advanced Serous Ovarian Cancer Is Associated with Unfavorable Overall Survival. PLoS ONE, 2013, 8, e60145.	1.1	43
45	Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study. Gynecologic Oncology, 2021, 161, 795-801.	0.6	43
46	RNA (E6 and E7) Assays versus DNA (E6 and E7) Assays for Risk Evaluation for Women Infected with Human Papillomavirus. Journal of Clinical Microbiology, 2009, 47, 2136-2141.	1.8	42
47	Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma. Gynecologic Oncology, 2021, 162, 401-406.	0.6	39
48	Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature. Gynecologic Oncology, 2022, 165, 192-197.	0.6	39
49	Detection of bacterial contamination in sterile UHT milk using an l-lactate biosensor. Enzyme and Microbial Technology, 1993, 15, 508-512.	1.6	38
50	TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma. Archives of Gynecology and Obstetrics, 2020, 301, 1117-1125.	0.8	38
51	Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer. Journal of Gynecologic Oncology, 2021, 32, e11.	1.0	38
52	Human Papillomavirus (HPV) Infection in Squamous Cell Carcinomas Arising From the Oropharynx: Detection of HPV DNA and p16 Immunohistochemistry as Diagnostic and Prognostic Indicators—A Pilot Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1115-1120.	0.4	37
53	Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases. European Journal of Surgical Oncology, 2019, 45, 2096-2102.	0.5	37
54	Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers. Oncotarget, 2016, 7, 8155-8171.	0.8	37

#	Article	IF	CITATIONS
55	Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile. Menopause, 2005, 12, 589-600.	0.8	36
56	Can radicality of surgery be safely modulated on the basis of MRI and PET/CT imaging in locally advanced cervical cancer patients administered preoperative treatment?. Cancer, 2012, 118, 392-403.	2.0	36
57	Morphological Effects of Radiochemotherapy on Cervical Carcinoma. International Journal of Gynecological Pathology, 2008, PAP, 274-81.	0.9	36
58	Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 193-198.	1.4	35
59	Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations. Annals of Surgical Oncology, 2017, 24, 3413-3421.	0.7	35
60	Intracranial Epithelioid Hemangioendothelioma: Case Report. Neurosurgery, 1996, 38, 399-401.	0.6	34
61	Prognostic Role of the Ratio between Cyclooxygenase-2 in Tumor and Stroma Compartments in Cervical Cancer. Clinical Cancer Research, 2004, 10, 3117-3123.	3.2	33
62	Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature. BMC Cancer, 2006, 6, 169.	1.1	33
63	Chromosome 9p deletion syndrome and sex reversal: Novel findings and redefinition of the critically deleted regions. American Journal of Medical Genetics, Part A, 2012, 158A, 2266-2271.	0.7	33
64	Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease. Frontiers in Oncology, 2019, 9, 778.	1.3	33
65	Follicular loss in endoscopic surgery for ovarian endometriosis: quantitative and qualitative observations. Fertility and Sterility, 2011, 96, 374-378.	0.5	32
66	Changes in the expression of oestrogen receptors and Eâ€cadherin as molecular markers of progression from normal epithelium to invasive cancer in elderly patients with vulvar squamous cell carcinoma. Histopathology, 2011, 58, 265-275.	1.6	32
67	Minimally Invasive Approach in Type II Endometrial Cancer: Is It Wise and Safe?. Journal of Minimally Invasive Gynecology, 2017, 24, 438-445.	0.3	32
68	Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases. Human Pathology, 2019, 92, 10-17.	1.1	32
69	Accuracy of One-Step Nucleic Acid Amplification in Detecting Lymph Node Metastases in Endometrial Cancer. Pathology and Oncology Research, 2020, 26, 2049-2056.	0.9	31
70	Neuroendocrine Carcinoma of the Uterine Cervix: A Clinicopathologic and Immunohistochemical Study with Focus on Novel Markers (Sst2–Sst5). Cancers, 2020, 12, 1211.	1.7	31
71	Cytologic and histologic samples from patients infected by the novel coronavirus 2019 SARSâ€CoVâ€2: An Italian institutional experience focusing on biosafety procedures. Cancer Cytopathology, 2020, 128, 317-320.	1.4	31
72	Frozen section examination of pelvic lymph nodes in endometrial and cervical cancer: accuracy in patients submitted to neoadjuvant treatments. Gynecologic Oncology, 2004, 94, 779-784.	0.6	30

#	Article	IF	CITATIONS
73	Soy Phytochemicals Decrease Nonsmall Cell Lung Cancer Growth In Female Athymic Mice. Journal of Nutrition, 2008, 138, 1360-1364.	1.3	30
74	Application of Liquid-Based Cytology to Fine-Needle Aspiration Biopsies of the Thyroid Gland. Frontiers in Endocrinology, 2012, 3, 57.	1.5	30
75	Hormone receptor expression profile of low-grade serous ovarian cancers. Gynecologic Oncology, 2017, 145, 352-360.	0.6	30
76	Prognostic role of metastasis tumor antigen 1 in patients with ovarian cancer: a clinical study. Human Pathology, 2012, 43, 282-288.	1.1	29
77	One-Step Nucleic Acid Amplification (OSNA): A fast molecular test based on CK19 mRNA concentration for assessment of lymph-nodes metastases in early stage endometrial cancer. PLoS ONE, 2018, 13, e0195877.	1.1	29
78	Diagnostic performance of preoperative [18F]FDG-PET/CT for lymph node staging in vulvar cancer: a large single-centre study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3303-3314.	3.3	28
79	Decreased expression of the CDK inhibitor p27Kip1 and increased oxidative DNA damage in the multistep process of cervical carcinogenesis. Gynecologic Oncology, 2004, 92, 776-783.	0.6	27
80	Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1647-1658.	1.2	27
81	Fine Needle Aspiration of a Warthin-like Thyroid Tumor. Acta Cytologica, 1998, 42, 998-1002.	0.7	26
82	A case of metastatic struma ovarii treated with ¹³¹ 1 therapy: Focus on preservation of fertility and selected review of the literature. Gynecological Endocrinology, 2008, 24, 312-319.	0.7	26
83	Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer. Gynecologic Oncology, 2017, 146, 170-178.	0.6	26
84	Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification. Gynecologic Oncology, 2021, 161, 629-635.	0.6	26
85	Relevance of Immunocytochemistry on Thin-layer Cytology in Thyroid Lesions Suspicious for Medullary Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2008, 16, 548-553.	0.6	25
86	The role of semiquantitative evaluation of lympho-vascular space invasion in early stage cervical cancer patients. Gynecologic Oncology, 2021, 162, 299-307.	0.6	25
87	Concomitant Radiochemotherapy plus Surgery in Locally Advanced Cervical Cancer: Update of Clinical Outcome and Cyclooxygenase-2 as Predictor of Treatment Susceptibility. Oncology, 2004, 67, 103-111.	0.9	23
88	Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo. Neuro-Oncology, 2009, 11, 250-259.	0.6	23
89	Stromal signatures in endometrioid endometrial carcinomas. Modern Pathology, 2014, 27, 631-639.	2.9	23
90	The vulvar immunohistochemical panel (VIP) project: molecular profiles of vulvar Paget's disease. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2211-2225.	1.2	23

#	Article	IF	CITATIONS
91	Female adnexal tumors of probable Wolffian origin: morphological, immunohistochemical, and molecular analysis of 15 cases. Modern Pathology, 2020, 33, 734-747.	2.9	23
92	Clear cell carcinoma of the endometrium. Gynecologic Oncology, 2022, 164, 658-666.	0.6	23
93	Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer. BMC Cancer, 2006, 6, 182.	1.1	22
94	Clinicopathologic and Immunohistochemical Features of Ovarian Clear Cell Carcinomas in Comparison With Type I and Type II Tumors. International Journal of Gynecological Pathology, 2012, 31, 507-516.	0.9	22
95	Frozen section accurately allows pathological characterization of endometrial cancer in patients with a preoperative ambiguous or inconclusive diagnoses: our experience. BMC Cancer, 2019, 19, 1096.	1.1	22
96	Pathological features, immunoprofile and mismatch repair protein expression status in uterine endometrioid carcinoma: focus on MELF pattern of myoinvasion. European Journal of Surgical Oncology, 2021, 47, 338-345.	0.5	22
97	Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis. Gynecologic Oncology, 2021, 162, 804-808.	0.6	22
98	Biosafety in surgical pathology in the era of SARS-Cov2 pandemia. A statement of the Italian Society of Surgical Pathology and Cytology. Pathologica, 2020, 112, 1-5.	1.3	22
99	Italian consensus conference on management of uterine sarcomas on behalf of S.I.C.O. (Societa') Tj ETQq1 3	1 0,784314 1.3	l rgBT /Overla
100	Aberrant expression of α-dystroglycan in cervical and vulvar cancer. Gynecologic Oncology, 2006, 103, 397-404.	0.6	20
101	Hepatocyte growth factor and transforming growth factor β1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. Arthritis and Rheumatism, 2006, 54, 3633-3639.	6.7	20
102	Standard ultrastaging compared to one-step nucleic acid amplification (OSNA) for the detection of sentinel lymph node metastases in early stage cervical cancer. International Journal of Gynecological Cancer, 2020, 30, 1871-1877.	1.2	20
103	Role of one-step nucleic acid amplification (OSNA) to detect sentinel lymph node low-volume metastasis in early-stage cervical cancer. International Journal of Gynecological Cancer, 2020, 30, 364-371.	1.2	20
104	Prognostic value of the TCGA molecular classification in uterine carcinosarcoma. International Journal of Gynecology and Obstetrics, 2022, 158, 13-20.	1.0	20
105	Standard ultra-staging compared to one-step nucleic acid amplification for the detection of sentinel lymph node metastasis in endometrial cancer patients: a retrospective cohort comparison. International Journal of Gynecological Cancer, 2020, 30, 372-377.	1.2	20
106	Estradiol and phytoestrogens differently influence the rodent postmenopausal mammary gland. Menopause, 2006, 13, 72-79.	0.8	19
107	Expression of the CDK inhibitor p27kip1 and oxidative DNA damage in non-neoplastic and neoplastic vulvar epithelial lesions. Modern Pathology, 2006, 19, 504-513.	2.9	19
108	Expression of class III Î ² tubulin in cervical cancer patients administered preoperative radiochemotherapy: Correlation with response to treatment and clinical outcome. Gynecologic Oncology, 2007, 104, 326-330.	0.6	19

#	Article	IF	CITATIONS
109	Molecular status of <i>PI3KCA</i> , <i>KRAS</i> and <i>BRAF</i> in ovarian clear cell carcinoma: an analysis of 63 patients. Journal of Clinical Pathology, 2016, 69, 1088-1092.	1.0	19
110	Ultrasoundâ€guided FNA cytology of groin lymph nodes improves the management of squamous cell carcinoma of the vulva: Results from a comparative cytohistological study. Cancer Cytopathology, 2019, 127, 514-520.	1.4	19
111	Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment. Oncotarget, 2016, 7, 68033-68043.	0.8	19
112	Endometrioid endometrial carcinomas with microcystic, elongated, and fragmented (MELF) type of myoinvasion: role of immunohistochemistry in the detection of occult lymph node metastases and their clinical significance. Human Pathology, 2017, 70, 6-13.	1.1	18
113	Fetal Doppler velocimetry and bronchopulmonary dysplasia risk among growth-restricted preterm infants: an observational study. BMJ Open, 2017, 7, e015232.	0.8	18
114	Gender Effect in Experimental Models of Human Medulloblastoma: Does the Estrogen Receptor β Signaling Play a Role?. PLoS ONE, 2014, 9, e101623.	1.1	18
115	The Role of Liquid Based Cytology and Ancillary Techniques in the Peritoneal Washing Analysis: Our Institutional Experience. PLoS ONE, 2017, 12, e0168625.	1.1	18
116	The Vulvar Immunohistochemical Panel (VIP) Project: Molecular Profiles of Vulvar Squamous Cell Carcinoma. Cancers, 2021, 13, 6373.	1.7	18
117	Expression of cyclooxygenase-2 (COX-2) in non-neoplastic and neoplastic vulvar epithelial lesions. Gynecologic Oncology, 2004, 92, 537-544.	0.6	17
118	Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients. Gynecologic Oncology, 2008, 111, 237-243.	0.6	17
119	Estrogen receptor \hat{I}^2 : Potential target for therapy in adult granulosa cell tumors?. Gynecologic Oncology, 2018, 150, 158-165.	0.6	17
120	Celecoxib Up-Regulates the Expression of the ζ Chain of T Cell Receptor Complex in Tumor-Infiltrating Lymphocytes in Human Cervical Cancer. Clinical Cancer Research, 2006, 12, 2055-2060.	3.2	16
121	Dual Inhibitor AEE78 Reduces Tumor Growth in Preclinical Models of Medulloblastoma. Translational Oncology, 2010, 3, 326-335.	1.7	16
122	The role of 18F-FDG-PET/CT in predicting the histopathological response in locally advanced cervical carcinoma treated by chemo-radiotherapy followed by radical surgery: a prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1228-1238.	3.3	16
123	TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review. Gynecologic Oncology, 2021, 163, 427-432.	0.6	16
124	Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group. Frontiers in Oncology, 2022, 12, 805613.	1.3	16
125	Effects of epidermal growth factor receptor blockade on ependymoma stem cells <i>in vitro</i> and in orthotopic mouse models. International Journal of Cancer, 2012, 131, E791-803.	2.3	15
126	How to improve MRI accuracy in detecting deep infiltrating colorectal endometriosis: MRI findings vs. laparoscopy and histopathology. Radiologia Medica, 2014, 119, 291-297.	4.7	15

#	Article	IF	CITATIONS
127	Mitochondrial estrogen receptor β2 drives antiapoptotic pathways in advanced serous ovarian cancer. Human Pathology, 2015, 46, 1138-1146.	1.1	15
128	FOXL2 molecular status in adult granulosa cell tumors of the ovary: A study of primary and metastatic cases. Oncology Letters, 2016, 12, 1159-1163.	0.8	15
129	MRI anatomy of parametrial extension to better identify local pathways of disease spread in cervical cancer. Diagnostic and Interventional Radiology, 2016, 22, 319-325.	0.7	15
130	Cervical cancer response to neoadjuvant chemoradiotherapy: MRI assessment compared with surgery. Acta Radiologica, 2016, 57, 1123-1131.	0.5	15
131	Prognostic impact of hysteroscopic resection of endometrial atypical hyperplasia-endometrioid intraepithelial neoplasia and early-stage cancer in combination with megestrol acetate. American Journal of Obstetrics and Gynecology, 2021, 224, 408-410.	0.7	15
132	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. Oncotarget, 2016, 7, 72654-72661.	0.8	15
133	External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response. International Journal of Gynecological Cancer, 2020, 30, 67-73.	1.2	14
134	Diagnostic and Prognostic Role of WT1 Immunohistochemical Expression in Uterine Carcinoma: A Systematic Review and Meta-Analysis across All Endometrial Carcinoma Histotypes. Diagnostics, 2020, 10, 637.	1.3	14
135	Aberrant non-canonical WNT pathway as key-driver of high-grade serous ovarian cancer development. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 321-322.	1.4	14
136	Dietary soy modulation of biochemical parameters in DMBA-induced mammary tumors. Cancer Letters, 2002, 186, 43-48.	3.2	13
137	Oligodendroglioma arising within a mature cystic ovarian teratoma: case report and review of the literature. Acta Obstetricia Et Gynecologica Scandinavica, 2002, 81, 896-897.	1.3	13
138	Intratumoral color Doppler analysis in endometrial carcinoma: is it clinically useful?. Gynecologic Oncology, 2003, 88, 298-303.	0.6	13
139	Secondary malignancies of the uterine cervix: a potential diagnostic pitfall. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 23-29.	1.4	13
140	Tamoxifen related Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT): A case report and literature review of this possible association. Pathology Research and Practice, 2019, 215, 1089-1092.	1.0	13
141	The role of sentinel node in early ovarian cancer: a systematic review. Minerva Medica, 2019, 110, 358-366.	0.3	13
142	Asymptomatic Intrathyroidal Parathyroid Adenoma. Acta Cytologica, 2004, 48, 437-440.	0.7	12
143	Cytoplasmic expression of oestrogen receptor beta (ERβ) as a prognostic factor in vulvar squamous cell carcinoma in elderly women. Histopathology, 2011, 59, 909-917.	1.6	12
144	The dualistic model of endometrial cancer: The challenge of classifying grade 3 endometrioid carcinoma. Gynecologic Oncology, 2012, 127, 262-263.	0.6	12

#	Article	IF	CITATIONS
145	Fusion imaging of ultrasound and MRI in the assessment of locally advanced cervical cancer: a prospective study. International Journal of Gynecological Cancer, 2020, 30, 456-465.	1.2	12
146	Endometriosis-associated Extraovarian Malignancies: A Challenging Question for the Clinician and the Pathologist. Anticancer Research, 2020, 40, 2429-2438.	0.5	12
147	Sexual dimorphism in medulloblastoma features. Histopathology, 2016, 68, 541-548.	1.6	11
148	Intra-operative assessment of sentinel lymph node status by one-step nucleic acid amplification assay (OSNA) in early endometrial cancer: a prospective study. International Journal of Gynecological Cancer, 2019, 29, 1016-1020.	1.2	11
149	Uterine tumor resembling ovarian sex-cord tumor: Conservative surgery with successful delivery and case series. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 256, 326-332.	0.5	11
150	Cyclooxygenase-2 expression in borderline ovarian tumors. Gynecologic Oncology, 2004, 95, 46-51.	0.6	10
151	Femur metastasis in carcinoma of the uterine cervix: a rare entity. Archives of Gynecology and Obstetrics, 2010, 281, 963-965.	0.8	10
152	Morphological and immunocytochemical diagnosis of thyroiditis: Comparison between conventional and liquidâ€based cytology. Diagnostic Cytopathology, 2012, 40, 404-409.	0.5	10
153	Trends in net survival from ovarian cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S107-S113.	0.6	10
154	Perivascular epithelioid cell tumors (PEComa) of the female genital tract: A challenging question for gynaecologic oncologist and pathologist. Gynecologic Oncology Reports, 2020, 33, 100603.	0.3	10
155	Hormonal Environment and HER2 Status in Extra-Mammary Paget's Disease (eMPD): A Systematic Literature Review and Meta-Analysis with Clinical Considerations. Diagnostics, 2020, 10, 1040.	1.3	10
156	Depth of Stromal Invasion as the Most Prognostically Relevant Regression System in Locally Advanced Cervical Cancer after Neoadjuvant Treatment: A Systematic Review and Meta-Analysis Grading. Diagnostics, 2021, 11, 1772.	1.3	10
157	Solitary Fibrous Tumors of the Female Genital Tract. American Journal of Surgical Pathology, 2022, 46, 363-375.	2.1	10
158	The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method. Gynecologic Oncology, 2022, 165, 585-593.	0.6	10
159	Management of adnexal cystic masses with unexpected intracystic vegetations detected during laparoscopy. Journal of Minimally Invasive Gynecology, 2005, 12, 502-507.	0.3	9
160	Accuracy of Papanicolaou Smears in Cervical Cancer Patients Treated With Radiochemotherapy Followed by Radical Surgery. American Journal of Clinical Pathology, 2008, 130, 787-794.	0.4	9
161	Colonic Carcinoma Metastatic to the Endometrium. International Journal of Surgical Pathology, 2011, 19, 787-790.	0.4	9
162	Clinicopathological analysis of mixed endometrial carcinomas: clinical relevance of different neoplastic components. Human Pathology, 2017, 62, 99-107.	1.1	9

#	Article	IF	CITATIONS
163	Description of a new biosafe procedure for cytological specimens from patients with COVIDâ€19 processed by liquidâ€based preparations. Cancer Cytopathology, 2020, 128, 905-909.	1.4	9
164	The Many Faces of Endometriosis-Related Neoplasms in the Same Patient: A Brief Report. Gynecologic and Obstetric Investigation, 2020, 85, 371-376.	0.7	9
165	Impact of adenomyosis on the prognosis of patients with endometrial cancer. International Journal of Gynecology and Obstetrics, 2021, , .	1.0	9
166	Classy cell carcinoma of the endometrium: A case report and review of the literature. Pathology Research and Practice, 2007, 203, 217-220.	1.0	8
167	Presumed early ovarian cancer with isolated tumor cells in para-aortic sentinel nodes. International Journal of Gynecological Cancer, 2019, 29, 216-220.	1.2	8
168	Serous ovarian carcinoma recurring as a heterologous carcinosarcoma. Journal of Obstetrics and Gynaecology Research, 2007, 33, 95-99.	0.6	7
169	PIK3CA in ovarian clear cell carcinoma. Human Pathology, 2014, 45, 2514.	1.1	7
170	Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study. Cancers, 2021, 13, 5152.	1.7	7
171	Ovarian serous carcinoma presenting with mediastinal lymphadenopathy 20Âmonths before the intraabdominal mass: Role of immunohistochemistry. Gynecologic Oncology, 2007, 104, 497-500.	0.6	6
172	Radical Surgery in Advanced Cervical Cancer Patients Receiving Bevacizumab-Containing Chemotherapy: A "Real Life Experience― International Journal of Gynecological Cancer, 2018, 28, 1569-1575.	1.2	6
173	Failure of ulipristal acetate treatment as an indication for uterine malignancy. Medicine (United) Tj ETQq1 1 0.78	34314 rgB 0.4	T /Qverlock 1(
174	Uncommon Mixed Endometrial-Myometrial Benign Tumors of the Reproductive Tract: Literature Review. Gynecologic and Obstetric Investigation, 2019, 84, 521-547.	0.7	6
175	Prognostic significance of atypical mitotic figures in smooth muscle tumors of uncertain malignant potential (STUMP) of the uterus and uterine adnexa. Apmis, 2021, 129, 165-169.	0.9	6
176	An Emerging Anti-p16 Antibody-BC42 Clone as an Alternative to the Current E6H4 for Use in the Female Genital Tract Pathological Diagnosis: Our Experience and a Review on p16ink4a Functional Significance, Role in Daily-Practice Diagnosis, Prognostic Potential, and Technical Pitfalls. Diagnostics, 2021, 11, 713	1.3	6
177	Disseminated peritoneal leiomyomatosis and malignant transformation: A case series in a single referral center. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 262, 21-27.	0.5	6
178	Clinical Characteristics of Patients with Endometrial Cancer and Adenomyosis. Cancers, 2021, 13, 4918.	1.7	6
179	Prognostic predictors in recurrent adult granulosa cell tumors of the ovary: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 2022, 306, 315-321.	0.8	6
180	A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: an analysis of 203 cases. Modern Pathology, 2022, 35, 794-807.	2.9	6

#	Article	IF	CITATIONS
181	Diagnostic accuracy of HNF1β, Napsin A and P504S/Alpha-Methylacyl-CoA Racemase (AMACR) as markers of endometrial clear cell carcinoma. Pathology Research and Practice, 2022, 237, 154019.	1.0	6
182	Robotic Splenectomy for Isolated Splenic Recurrence of Endometrial Adenocarcinoma. Journal of Minimally Invasive Gynecology, 2018, 25, 774-775.	0.3	5
183	Capillary electrophoresis as alternative method to detect tumor genetic mutations: the model built on the founder BRCA1 c.4964_4982del19 variant. Familial Cancer, 2019, 18, 29-35.	0.9	5
184	Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4. Cancers, 2019, 11, 1349.	1.7	5
185	Clinical and ultrasound characteristics of the microcystic elongated and fragmented (MELF) pattern in endometrial cancer according to the International Endometrial Tumor Analysis (IETA) criteria. International Journal of Gynecological Cancer, 2019, 29, 119-125.	1.2	5
186	A possible interplay between HRâ€HPV and stemness in tumor development: an in vivo investigation of CD133 as a putative marker of cancer stem cell in HPV18â€infected KB cell line. Apmis, 2020, 128, 637-646.	0.9	5
187	Histopathological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) as Predictive Biomarker for Hormone Receptors Status, Proliferative Activity and Clinical Outcome in Her-2 Positive Breast Cancer. Applied Sciences (Switzerland), 2021, 11, 6788.	1.3	5
188	The Wide Morphological Spectrum of Deep (Aggressive) Angiomyxoma of the Vulvo-Vaginal Region: A Clinicopathologic Study of 36 Cases, including Recurrent Tumors. Diagnostics, 2021, 11, 1360.	1.3	5
189	Clear cell endometrial carcinoma precursors: presentation of two cases and diagnostic issues. Diagnostic Pathology, 2021, 16, 95.	0.9	5
190	"Clock mapping―prior to excisional surgery in vulvar Paget's disease: tailoring the surgical plan. Archives of Gynecology and Obstetrics, 2022, , 1.	0.8	5
191	Accuracy of cytological examination of Tao Brush endometrial sampling in diagnosing endometrial premalignancy and malignancy. International Journal of Gynecology and Obstetrics, 2022, , .	1.0	5
192	Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis. Cancers, 2022, 14, 1934.	1.7	5
193	A Rare Case of Perirenal Myelolipoma: Diagnostic Approach and Therapeutic Strategy. Scandinavian Journal of Urology and Nephrology, 1997, 31, 579-581.	1.4	4
194	Amoxicillin-Induced Nephritis and Tubulitis in a Child. Urologia Internationalis, 2003, 71, 124-126.	0.6	4
195	Is frozen section analysis of pelvic lymph nodes accurate in locally advanced cervical cancer patients administered preoperative chemoradiation?. Gynecologic Oncology, 2008, 108, 220-225.	0.6	4
196	Morphology and Immunophenotyping of a Monolateral Ovotestis in a 46,XderY/45,X Mosaic Individual With Ambiguous Genitalia. International Journal of Gynecological Pathology, 2010, 29, 33-38.	0.9	4
197	Evaluation of Beta-Catenin Subcellular Localization and Water Channel Protein AQP1 Expression as Predictive Markers of Chemo-Resistance in Ovarian High-Grade Serous Carcinoma: Comparative Study between Preoperative Peritoneal Biopsies and Surgical Samples. Diagnostics, 2021, 11, 452.	1.3	4
198	Stanford parameters stratify the risk of recurrence in gynecologic smooth muscle tumors of uncertain malignant potential. Apmis, 2021, 129, 283-290.	0.9	4

#	Article	IF	CITATIONS
199	Bowel Endometriosis with Hemoperitoneum Complicating Pregnancy. Journal of Endometriosis and Pelvic Pain Disorders, 2013, 5, 166-169.	0.3	4
200	SATB2 is expressed in neuroendocrine carcinoma of the uterine cervix. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 873-877.	1.4	4
201	Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis. Diagnostics, 2022, 12, 633.	1.3	4
202	Biomarker characterization in endometrial cancer in Italy: first survey data analysis. Pathologica, 2022, 114, 189-198.	1.3	4
203	Contrast-enhanced ultrasonography in chronic glomerulonephritides: correlation with histological parameters of disease activity. Journal of Ultrasound, 2018, 21, 81-87.	0.7	3
204	Cerebellar Metastasis From Ovarian Carcinoma Harboring PIK3CA-Activating Mutation. International Journal of Gynecological Pathology, 2020, 39, 68-71.	0.9	3
205	Neuroendocrine tumor (NET) of the vagina in the light of WHO 2020 2-tiered grading system: clinicopathological report of the first described case. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, , 1.	1.4	3
206	Risk of Recurrence in Uterine Leiomyoma with Bizarre Nuclei: a Systematic Review and Meta-Analysis. Geburtshilfe Und Frauenheilkunde, 2021, 81, 1217-1223.	0.8	3
207	Histological Prognostic Factors of Endometrial Cancer in Patients with Adenomyosis: A Systematic Review and Meta-Analysis. Pathobiology, 2022, 89, 127-134.	1.9	3
208	Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients. Cancers, 2022, 14, 1849.	1.7	3
209	P504S/alpha-methylacyl-CoA racemase, HNF1β and napsin A in morular metaplasia and clear cell carcinoma of the endometrium: An immunohistochemical analysis. Pathology Research and Practice, 2022, 236, 153953.	1.0	3
210	Survivin protein as predictor of pathologic response in patients with locally advanced cervical cancer treated with chemoradiation followed by radical surgery. Human Pathology, 2014, 45, 1872-1878.	1.1	2
211	Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer. Translational Oncology, 2018, 11, 358-365.	1.7	2
212	Malignant peritoneal mesothelioma in a woman with bilateral ovarian serous borderline tumour: Potential interactions between the two diseases. Gynecologic Oncology Reports, 2018, 24, 39-42.	0.3	2
213	Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes. International Journal of Gynecological Cancer, 2019, 29, 1064-1071.	1.2	2
214	Role of Retinoblastoma Protein Family (Rb/p105 and Rb2/p130) Expression in the Histopathological Classification of Borderline Ovarian Tumors. Frontiers in Medicine, 2020, 7, 596226.	1.2	2
215	Peritoneal Carcinomatosis From Yolk Sac Tumor in a Postmenopausal Woman Following Chemotherapy for High-grade Ovarian Serous Carcinoma. International Journal of Gynecological Pathology, 2020, 39, e2-e3.	0.9	2
216	Multicentre Evaluation of Hepika Test Clinical Accuracy in Diagnosing HPV-Induced Cancer and Precancerous Lesions of the Uterine Cervix. Diagnostics, 2021, 11, 619.	1.3	2

#	Article	IF	CITATIONS
217	Melanocyte Colonization and Pigmentation of Breast Carcinoma: Description of Two Pathological Cases and Review of Literature. Diagnostics, 2021, 11, 709.	1.3	2
218	Diagnostic impact of safety protocols for processing peritoneal washing specimens during global pandemicÂofÂCoronavirus disease 2019Â: a comparative study from 195 cytological samples. Cytopathology, 2021, , .	0.4	2
219	Stem cell markers in oral and oropharyngeal squamous cell carcinomas in relation to the site of origin and HPV infection: clinical implications. Acta Otorhinolaryngologica Italica, 2020, 40, 90-98.	0.7	2
220	Biosafety procedures for handling intraoperative surgical samples during COVID-19 pandemic: an Italian pathology laboratory experience. Pathologica, 2020, 112, 174-177.	1.3	2
221	Assessing Post-Treatment Pathologic Tumor Response in Female Genital Tract Carcinomas: An Update. Frontiers in Oncology, 2022, 12, 814989.	1.3	2
222	Endometrial giant cell carcinoma: new insights from a morphological, immunohistochemical, and molecular analysis of three cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 321-326.	1.4	2
223	Endometrial Metaplastic/Reactive Changes Coexistent with Endometrial Hyperplasia and Carcinoma: A Morphological and Immunohistochemical Study. Diagnostics, 2022, 12, 63.	1.3	2
224	Prognostic role of perineural invasion in vulvar squamous cell carcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2022, 48, 2354-2359.	0.5	2
225	Ovarian endomyometrioma with atypias: description of a case. Fertility and Sterility, 2007, 88, 1438.e15-1438.e17.	0.5	1
226	A case of isolated ovarian recurrence from vulvar carcinoma. Archives of Gynecology and Obstetrics, 2008, 278, 393-396.	0.8	1
227	Should a renal biopsy be performed at the first relapse of â€~clinical nephrotic syndrome'?. Scandinavian Journal of Urology and Nephrology, 2008, 42, 184-186.	1.4	1
228	Borderline Mucinous Endocervical Tumor as a Link Between the Endometriotic Cyst and Ovarian Primary Squamous Cell Carcinoma. International Journal of Gynecological Pathology, 2011, 30, 396-397.	0.9	1
229	The Family of β-Catenin Ovarian Tumors. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, e95-e99.	0.6	1
230	Endometrial carcinoma in a single horn of a bicornuate uterus: A case report. Journal of the Egyptian National Cancer Institute, 2018, 30, 81-83.	0.6	1
231	A new entity in the pathological spectrum of vulvar neoplasms: The first report of a primary endometrioid adenocarcinoma. International Journal of Gynecology and Obstetrics, 2019, 147, 270-272.	1.0	1
232	Ovarian Clear Cell Carcinoma: From Morphology to Molecular Biology. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 631-636.	0.6	1
233	Gardnerella vaginalis and Trichomonas vaginalis infections and the risk of persistence or progression of low-grade cervical intraepithelial neoplasia. Pathology Research and Practice, 2020, 216, 153234.	1.0	1
234	The role of cytology in endometrial cancer: Diagnostic and clinical considerations from peritoneal/pelvic washings. Is it still a heated debate?. Cancer Cytopathology, 2021, 129, 497-498.	1.4	1

#	Article	IF	CITATIONS
235	Clinicopathological Features Associated with Microsatellite Instability/Mismatch Repair Deficiency in Uterine Carcinosarcoma: A Quantitative Systematic Review. Pathobiology, 2022, 89, 198-204.	1.9	1
236	Cytoplasmic expression of human papilloma virus L1 capsidic protein in mammary and extramammary Paget disease. Histopathology, 2013, 63, 139-142.	1.6	0
237	Abstract 4055: Class III β-tubulin and the cytoskeletal gateway of drug resistance in ovarian cancer. , 2011, , .		0
238	Abstract 4522: Androgen receptor is a main driver of aggressiveness in colorectal cancer through the class III β-tubulin pathway. , 2012, , .		0
239	Editorial: Future Perspectives of Sentinel Node Mapping in Gynecological Oncology. Frontiers in Oncology, 2022, 12, 809765.	1.3	0
240	TLR4 Expression in Ex-Lichenoid Lesions—Oral Squamous Cell Carcinomas and Its Surrounding Epithelium: The Role of Tumor Inflammatory Microenvironment. Biomolecules, 2022, 12, 385.	1.8	0